MENU

HALO Stock Halozyme Therapeutics (HALO, $57.9) RSI Indicator left the overbought zone on February 18, 2025

A.I.dvisor
at Tickeron.com
Loading...
HALO - Halozyme Therapeutics
RSI signal
Bearish Trend
Odds of DOWN Trend
Tickeron
RSI signal
Price: $57.9
Daily change: -$0.39 (-0.67%)
Daily volume: 1.7M
Industry: Biotechnology
This is a signal that HALO's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options. A.I.dvisor looked back and found 39 similar cases where HALO's RSI Indicator left the overbought zone, and in of them led to a successful outcome. Odds of Success:

HALO in downward trend: price expected to drop as it breaks its higher Bollinger Band on February 05, 2025

HALO broke above its upper Bollinger Band on February 05, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 41 similar instances where the stock broke above the upper band. In of the 41 cases the stock fell afterwards. This puts the odds of success at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for HALO moved out of overbought territory on February 18, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 58 cases where HALO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on February 20, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on HALO as a result. In of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for HALO turned negative on February 07, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HALO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HALO advanced for three days, in of 312 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 279 cases where HALO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HALO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.531) is normal, around the industry mean (12.496). P/E Ratio (16.828) is within average values for comparable stocks, (84.451). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.603). HALO has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (7.358) is also within normal values, averaging (251.218).

View a ticker or compare two or three
HALO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of recombinant human enzymes for the infertility, ophthalmology and oncology markets

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
12390 El Camino Real
Phone
+1 858 794-8889
Employees
373
Web
https://www.halozyme.com